Switch theme
Sign up to access all valuation multiples
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer’s disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
2012
163
LTM Revenue $93.4M
Last FY EBITDA -$154M
-$160M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Prothena Corp. has a last 12-month revenue (LTM) of $93.4M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Prothena Corp. achieved revenue of $135M and an EBITDA of -$154M.
Prothena Corp. expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Prothena Corp. valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $93.4M | XXX | $135M | XXX | XXX | XXX |
| Gross Profit | $93.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$154M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -114% | XXX | XXX | XXX |
| EBIT | -$183M | XXX | -$155M | XXX | XXX | XXX |
| EBIT Margin | -196% | XXX | -114% | XXX | XXX | XXX |
| Net Profit | -$155M | XXX | -$122M | XXX | XXX | XXX |
| Net Margin | -166% | XXX | -90% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Prothena Corp.'s stock price is $5.
Prothena Corp. has current market cap of $248M, and EV of -$160M.
See Prothena Corp. trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$160M | $248M | XXX | XXX | XXX | XXX | $-2.85 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Prothena Corp. has market cap of $248M and EV of -$160M.
Prothena Corp.'s trades at -1.2x EV/Revenue multiple, and 1.0x EV/EBITDA.
Equity research analysts estimate Prothena Corp.'s 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Prothena Corp. has a P/E ratio of -1.6x.
See valuation multiples for Prothena Corp. and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $248M | XXX | $248M | XXX | XXX | XXX |
| EV (current) | -$160M | XXX | -$160M | XXX | XXX | XXX |
| EV/Revenue | -1.7x | XXX | -1.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBIT | 0.9x | XXX | 1.0x | XXX | XXX | XXX |
| EV/Gross Profit | -1.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.6x | XXX | -2.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 1.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialProthena Corp.'s last 12 month revenue growth is -46%
Prothena Corp.'s revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $1.8M for the same period.
Prothena Corp.'s rule of 40 is -254% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Prothena Corp.'s rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Prothena Corp. and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -46% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -114% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -254% | XXX | -160% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 165% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 214% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Prothena Corp. acquired XXX companies to date.
Last acquisition by Prothena Corp. was XXXXXXXX, XXXXX XXXXX XXXXXX . Prothena Corp. acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Prothena Corp. founded? | Prothena Corp. was founded in 2012. |
| Where is Prothena Corp. headquartered? | Prothena Corp. is headquartered in United States of America. |
| How many employees does Prothena Corp. have? | As of today, Prothena Corp. has 163 employees. |
| Who is the CEO of Prothena Corp.? | Prothena Corp.'s CEO is Dr. Gene G. Kinney, PhD. |
| Is Prothena Corp. publicy listed? | Yes, Prothena Corp. is a public company listed on NAS. |
| What is the stock symbol of Prothena Corp.? | Prothena Corp. trades under PRTA ticker. |
| When did Prothena Corp. go public? | Prothena Corp. went public in 2012. |
| Who are competitors of Prothena Corp.? | Similar companies to Prothena Corp. include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Prothena Corp.? | Prothena Corp.'s current market cap is $248M |
| What is the current revenue of Prothena Corp.? | Prothena Corp.'s last 12 months revenue is $93.4M. |
| What is the current revenue growth of Prothena Corp.? | Prothena Corp. revenue growth (NTM/LTM) is -46%. |
| What is the current EV/Revenue multiple of Prothena Corp.? | Current revenue multiple of Prothena Corp. is -1.7x. |
| Is Prothena Corp. profitable? | Yes, Prothena Corp. is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
